Success Continues to Be Evasive
While Flurizan was expected to treat the underlying causes of the disease, the four currently marketed treatments simply alleviate symptoms. Several drugs that aim to prevent plaque production are in Phase III trials.
No one believes that developing new AD drugs is easy; over 20 have failed Phase III since 2002. AD patients and their physicians, however, are ill-served by the uber-hype engendered by results from poorly controlled clinical trials and pharma company tap dancing.